Eric P. Suan, M.D., F.A.C.S. is a Retina Specialist & Vitreoretinal Surgeon and Founder of The Retina Care Center with offices in Maryland, Pennsylvania & Delaware. He provides state-of-the-art medical and surgical treatments for diseases of the retina and vitreous in multiple locations throughout Maryland and Pennsylvania. His areas of interest and expertise are medical and surgical management of Diabetic Retinopathy, Macular Degeneration, Macular Holes and Puckers, complex Retinal Detachments, and Complications of Ocular Surgery.

Dr. Suan established the Research Department of The Retina Care Center in 2006. He has been the Principal Investigator for over 36 Phase 2, 3, and 4 clinical trials. Many of these pivotal studies have led to the FDA approval of medications used to treat wet AMD, Diabetic Retinopathy and Retinal Vein Occlusions. His current areas of research include novel treatments and gene therapy for dry AMD, more efficacious and or longer acting medications and new medication delivery systems for wet AMD and Diabetic Retinopathy.

Eric P. Suan, M.D., F.A.C.S. is a Retina Specialist & Vitreoretinal Surgeon and Founder of The Retina Care Center with offices in Maryland, Pennsylvania & Delaware. He provides state-of-the-art medical and surgical treatments for diseases of the retina and vitreous in multiple locations throughout Maryland and Pennsylvania. His areas of interest and expertise are medical and surgical management of Diabetic Retinopathy, Macular Degeneration, Macular Holes and Puckers, complex Retinal Detachments, and Complications of Ocular Surgery.

Dr. Suan established the Research Department of The Retina Care Center in 2006. He has been the Principal Investigator for over 36 Phase 2, 3, and 4 clinical trials. Many of these pivotal studies have led to the FDA approval of medications used to treat wet AMD, Diabetic Retinopathy and Retinal Vein Occlusions. His current areas of research include novel treatments and gene therapy for dry AMD, more efficacious and or longer acting medications and new medication delivery systems for wet AMD and Diabetic Retinopathy.

Eric P. Suan, M.D., F.A.C.S. is a Retina Specialist & Vitreoretinal Surgeon and Founder of The Retina Care Center with offices in Maryland, Pennsylvania & Delaware. He provides state-of-the-art medical and surgical treatments for diseases of the retina and vitreous in multiple locations throughout Maryland and Pennsylvania. His areas of interest and expertise are medical and surgical management of Diabetic Retinopathy, Macular Degeneration, Macular Holes and Puckers, complex Retinal Detachments, and Complications of Ocular Surgery.

Dr. Suan established the Research Department of The Retina Care Center in 2006. He has been the Principal Investigator for over 36 Phase 2, 3, and 4 clinical trials. Many of these pivotal studies have led to the FDA approval of medications used to treat wet AMD, Diabetic Retinopathy and Retinal Vein Occlusions. His current areas of research include novel treatments and gene therapy for dry AMD, more efficacious and or longer acting medications and new medication delivery systems for wet AMD and Diabetic Retinopathy.

Eric P. Suan, M.D., F.A.C.S. is a Retina Specialist & Vitreoretinal Surgeon and Founder of The Retina Care Center with offices in Maryland, Pennsylvania & Delaware. He provides state-of-the-art medical and surgical treatments for diseases of the retina and vitreous in multiple locations throughout Maryland and Pennsylvania. His areas of interest and expertise are medical and surgical management of Diabetic Retinopathy, Macular Degeneration, Macular Holes and Puckers, complex Retinal Detachments, and Complications of Ocular Surgery.

Dr. Suan established the Research Department of The Retina Care Center in 2006. He has been the Principal Investigator for over 36 Phase 2, 3, and 4 clinical trials. Many of these pivotal studies have led to the FDA approval of medications used to treat wet AMD, Diabetic Retinopathy and Retinal Vein Occlusions. His current areas of research include novel treatments and gene therapy for dry AMD, more efficacious and or longer acting medications and new medication delivery systems for wet AMD and Diabetic Retinopathy.